Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 11;100(6):1537–1546. doi: 10.1007/s00277-021-04447-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021, corrected publication 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — SLAMF7 expression on intramedullary and extramedullary myeloma cells prior to elotuzumab treatment. Giemsa (a, d) and immunohistochemical staining for CD138 (b, e) as well as SLAMF7 (c, f) in the bone marrow (a-c) and in a skin biopsy (d-f) obtained simultaneously prior to elotuzumab treatment (a-f: original magnification ×400; length of the scale bar in d: 50 μm). SLAMF7 shows a strong and consistent expression in the CD138-positive myeloma cells. VCD, bortezomib/cyclophosphamide/dexamethasone; HD-Mel/autoSCT, high-dose melphalan/autologous stem cell transplantation; Len-MT, lenalidomide maintenance; Dara, daratumumab; KRd, carfilzomib/lenalidomide/dexamethasone; BM, bone marrow; EMD, extramedullary disease; VTD-PACE, bortezomib/thalidomide/dexamethasone-cisplatin/adriamycin/cyclophosphamide/etoposide); EloPd, elotuzumab/pomalidomide/dexamethasone; BSC, best supportive care